Jayanthi Lea

4.9k total citations · 1 hit paper
116 papers, 2.6k citations indexed

About

Jayanthi Lea is a scholar working on Obstetrics and Gynecology, Reproductive Medicine and Epidemiology. According to data from OpenAlex, Jayanthi Lea has authored 116 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Obstetrics and Gynecology, 35 papers in Reproductive Medicine and 32 papers in Epidemiology. Recurrent topics in Jayanthi Lea's work include Endometrial and Cervical Cancer Treatments (59 papers), Ovarian cancer diagnosis and treatment (33 papers) and Cervical Cancer and HPV Research (28 papers). Jayanthi Lea is often cited by papers focused on Endometrial and Cervical Cancer Treatments (59 papers), Ovarian cancer diagnosis and treatment (33 papers) and Cervical Cancer and HPV Research (28 papers). Jayanthi Lea collaborates with scholars based in United States, Canada and China. Jayanthi Lea's co-authors include David S. Miller, John O. Schorge, Jinming Gao, Min Luo, Yang-Xin Fu, Zhigang Lu, Gang Huang, Matthew R. Porembka, Zhaohui Wang and Mingjian Du and has published in prestigious journals such as Cell, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Jayanthi Lea

108 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A STING-activating nanovaccine for cancer immunotherapy

2017 752 citations Min Luo, Hua Wang et al. Nature Nanotechnology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jayanthi Lea United States	27	880	870	694	610	483	116	2.6k
Tatsuya Ishiguro Japan	23	703 0.8×	326 0.4×	574 0.8×	359 0.6×	155 0.3×	95	2.2k
Nathalie Scholler United States	31	1.1k 1.3×	1.1k 1.3×	1.5k 2.2×	283 0.5×	91 0.2×	73	3.5k
Bor‐Ching Sheu Taiwan	29	363 0.4×	778 0.9×	590 0.9×	751 1.2×	276 0.6×	122	2.6k
Willemien J. van Driel Netherlands	27	749 0.9×	632 0.7×	625 0.9×	549 0.9×	529 1.1×	94	3.6k
Lukáš Rob Czechia	31	434 0.5×	669 0.8×	1.5k 2.2×	1.4k 2.3×	1.1k 2.3×	129	3.3k
Carolyn Y. Muller United States	35	1.2k 1.4×	240 0.3×	972 1.4×	481 0.8×	498 1.0×	104	3.4k
Setsuko K. Chambers United States	42	1.4k 1.6×	605 0.7×	871 1.3×	1.0k 1.7×	409 0.8×	118	4.2k
Alexander Burnett United States	29	498 0.6×	336 0.4×	855 1.2×	1.0k 1.7×	571 1.2×	57	2.8k
Antonella Ravaggi Italy	34	783 0.9×	967 1.1×	833 1.2×	490 0.8×	875 1.8×	104	3.3k
Scott K. Pruitt United States	33	1.1k 1.3×	1.6k 1.8×	2.1k 3.0×	273 0.4×	542 1.1×	87	4.0k

Countries citing papers authored by Jayanthi Lea

Since Specialization

Citations

This map shows the geographic impact of Jayanthi Lea's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jayanthi Lea with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jayanthi Lea more than expected).

Fields of papers citing papers by Jayanthi Lea

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jayanthi Lea. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jayanthi Lea. The network helps show where Jayanthi Lea may publish in the future.

Co-authorship network of co-authors of Jayanthi Lea

This figure shows the co-authorship network connecting the top 25 collaborators of Jayanthi Lea. A scholar is included among the top collaborators of Jayanthi Lea based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jayanthi Lea. Jayanthi Lea is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yu, Xuexin, et al.. (2024). Quantifiable TCR repertoire changes in prediagnostic blood specimens among patients with high-grade ovarian cancer. Cell Reports Medicine. 5(7). 101612–101612. 5 indexed citations

Chen, Hao, Kyle Molberg, Kelley Carrick, et al.. (2024). Expression and Prognostic Significance of LAG-3, TIGIT, VISTA, and IDO1 in Endometrial Serous Carcinoma. Modern Pathology. 37(8). 100532–100532. 4 indexed citations

Camacho, Cristel V., et al.. (2024). Abstract #6: RBN-2397, a PARP7 Inhibitor, Synergizes with Paclitaxel to Inhibit Proliferation and Migration of Ovarian Cancer Cells. Gynecologic Oncology Reports. 57. 101557–101557.

Kvale, Elizabeth, Farya Phillips, Samiran Ghosh, et al.. (2023). Survivorship Care for Women Living With Ovarian Cancer: Protocol for a Randomized Controlled Trial. JMIR Research Protocols. 13. e48069–e48069.

Miller, David S., Matthew L. Carlson, Jayanthi Lea, et al.. (2022). 2022-RA-722-ESGO Phase 2 study assessing the efficacy of adding AL3818 (Catequentinib Dihydrochloride, Anlotinib Hydrochloride) to chemotherapies in subjects with platinum resistant ovarian carcinoma. International Journal of Gynecological Cancer. 32. A259–A259.

Lea, Jayanthi, et al.. (2022). 24 The PARP-1-DDX21-ribosome biogenesis axis is an alternative pathway targeted by PARP inhibitors in ovarian cancer. Gynecologic Oncology Reports. 44. S11–S12. 1 indexed citations

Carlson, Matthew J., et al.. (2020). Stage IVA cervical cancer: outcomes of disease related complications and treatment. International Journal of Gynecological Cancer. 31(4). 518–523. 7 indexed citations

Onabolu, Oreoluwa, Wenxin Zheng, Yang‐Xin Fu, et al.. (2020). De novo prediction of cancer-associated T cell receptors for noninvasive cancer detection. Science Translational Medicine. 12(557). 58 indexed citations

Jetelina, Katelyn K., Christian Carr, Caitlin C. Murphy, et al.. (2020). The impact of intimate partner violence on breast and cervical cancer survivors in an integrated, safety-net setting. Journal of Cancer Survivorship. 14(6). 906–914. 16 indexed citations

10.

Lee, Jessica, et al.. (2020). Practice patterns using minimally invasive surgery for the treatment of ovarian cancer: A survey of physician members of the Society of Gynecologic Oncologists. Gynecologic Oncology Reports. 33. 100617–100617. 3 indexed citations

11.

Conrad, Lesley B., Ken Y. Lin, Tulip Nandu, et al.. (2019). ADP-Ribosylation Levels and Patterns Correlate with Gene Expression and Clinical Outcomes in Ovarian Cancers. Molecular Cancer Therapeutics. 19(1). 282–291. 18 indexed citations

12.

Albuquerque, Kevin, Vasu Tumati, Jayanthi Lea, et al.. (2019). A Phase II Trial of Stereotactic Ablative Radiation Therapy as a Boost for Locally Advanced Cervical Cancer. International Journal of Radiation Oncology*Biology*Physics. 106(3). 464–471. 66 indexed citations

13.

Conrad, Lesley B., et al.. (2018). Pre‐operative core muscle index in combination with hypoalbuminemia is associated with poor prognosis in advanced ovarian cancer. Journal of Surgical Oncology. 117(5). 1020–1028. 32 indexed citations

14.

Luo, Min, Hua Wang, Zhaohui Wang, et al.. (2017). A STING-activating nanovaccine for cancer immunotherapy. Nature Nanotechnology. 12(7). 648–654. 752 indexed citations breakdown →

15.

Ahsen, Mehmet Eren, Todd Boren, Nitin K. Singh, et al.. (2017). Sparse feature selection for classification and prediction of metastasis in endometrial cancer. BMC Genomics. 18(S3). 233–233. 19 indexed citations

16.

Moore, Kathleen N., Karen A. Cadoo, Suzanne K. Chambers, et al.. (2017). A multicentre phase II study of AZD1775 plus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Annals of Oncology. 28. v352–v353. 2 indexed citations

17.

Lin, Ken Y., et al.. (2014). Malignant ovarian germ cell tumor — Role of surgical staging and gonadal dysgenesis. Gynecologic Oncology. 134(1). 84–89. 32 indexed citations

18.

Carbon, Juliet G., Andrew F. Miller, Emely Castro‐Rivera, et al.. (2008). Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity. American Journal of Obstetrics and Gynecology. 200(2). 180.e1–180.e7. 17 indexed citations

19.

Schorge, John O., et al.. (2004). P16 as a molecular biomarker of cervical adenocarcinoma. American Journal of Obstetrics and Gynecology. 190(3). 668–673. 40 indexed citations

20.

Lea, Jayanthi, Robert L. Coleman, John O. Schorge, et al.. (2004). Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis. American Journal of Obstetrics and Gynecology. 190(3). 674–679. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact